Print this page
-
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Protocol: 001720Applicable Disease Sites: Liver
-
Optimizing Colorectal Cancer Screening Among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches.
Protocol: 002056Applicable Disease Sites: Colon
-
Preoperative Plasma ctDNA Detection in Early Stage Cancer: A Proof-of-Concept Evaluation
Protocol: 032308Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Colon
Lung -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Liver -
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.
Protocol: 072107Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Pancreas -
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.
Protocol: 072108Applicable Disease Sites: Pancreas
-
A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery.
Protocol: 072201Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum -
A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE).
Protocol: 072204Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Esophagus
Stomach -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Understanding the Role of Pepsinogen and Gut Microbiome as a Biomarker of Cancer in the Gastrointestinal Tract.
Protocol: 072208Principal Investigator:
- Haejin In
Applicable Disease Sites: Stomach -
Pilot Study of Stomach Cancer Early Detection and Prevention with Endoscopy (Pilot-SCREEN).
Protocol: 072211Principal Investigator:
- Haejin In
Applicable Disease Sites: Stomach -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
- Sharon Li
Applicable Disease Sites: Liver -
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon